| Vaccines | Production and marketing of pediatric and combination vaccines targeting infectious diseases. | Strong patents, WHO cGMP compliant manufacturing, exclusive technology licenses, and government collaborations. | Government health programs, UN agencies like UNICEF, healthcare providers (B2G, B2B). | Combination vaccines like hexavalent EasySix™ with unique patented formulations. | 3098 | 55 | Revenue via vaccine sales to governments, UN agencies, and healthcare providers with some grant income. | Contract sales largely with fixed-price government tenders and agency agreements. | Rising demand for combination vaccines, global immunization programs, government incentives, new product launches. | EasySix™, Easyfour-TT™, EasyFourPol@ |
| Pharmaceutical Formulations | Anti-diabetic, oncology, pain management, orthopedic and baby care nutritional products. | In-house R&D innovation, strategic collaborations, strong brand equity in niche pharma categories. | Pharmacies, hospitals, healthcare professionals, end consumers (B2B, B2C). | Specialty oncology drugs and branded pediatric nutrition products. | 2492 | 45 | Sales of generic and branded formulations via domestic and international pharmaceutical channels. | Direct sales, branded generics, and licensing arrangements internationally. | Introduction of new product lines, oncology segment growth, baby care expansion, international generics licensing. | Tacpan®, Glizid M V, Calcom Plus, RF Willgo, Paclitaxel protein-bound nanoparticles |
